Alkermes plc Logo

Alkermes plc

ALKS

(1.8)
Stock Price

29,71 USD

13.6% ROA

26.49% ROE

15.8x PER

Market Cap.

4.464.149.480,00 USD

23.01% DER

0% Yield

22.15% NPM

Alkermes plc Stock Analysis

Alkermes plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Alkermes plc Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (18.33%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 DER

The stock has a minimal amount of debt (21%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROA

The stock's ROA (9.87%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 PBV

The stock's PBV ratio (2.98x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

5 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (136) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Alkermes plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Alkermes plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Alkermes plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Alkermes plc Revenue
Year Revenue Growth
1992 1.700.000
1993 9.500.000 82.11%
1994 7.800.000 -21.79%
1995 12.300.000 36.59%
1996 14.000.000 12.14%
1997 19.826.947 29.39%
1998 31.326.648 36.71%
1999 43.715.586 28.34%
2000 22.920.357 -90.73%
2001 56.029.865 59.09%
2002 54.101.513 -3.56%
2003 47.266.225 -14.46%
2004 39.054.017 -21.03%
2005 76.126.000 48.7%
2006 166.601.000 54.31%
2007 239.965.000 30.57%
2008 240.717.000 0.31%
2009 326.839.000 26.35%
2010 178.281.000 -83.33%
2011 186.640.000 4.48%
2012 389.977.000 52.14%
2013 575.548.000 32.24%
2014 618.789.000 6.99%
2015 628.335.000 1.52%
2016 745.694.000 15.74%
2017 903.374.000 17.45%
2018 1.094.274.000 17.45%
2019 1.170.947.000 6.55%
2020 1.038.756.000 -12.73%
2021 1.173.751.000 11.5%
2022 1.111.795.000 -5.57%
2023 1.523.752.000 27.04%
2023 1.663.405.000 8.4%
2024 1.596.524.000 -4.19%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Alkermes plc Research and Development Expenses
Year Research and Development Expenses Growth
1992 0
1993 0 0%
1994 20.500.000 100%
1995 19.000.000 -7.89%
1996 21.600.000 12.04%
1997 29.553.988 26.91%
1998 31.339.121 5.7%
1999 48.456.824 35.33%
2000 54.482.672 11.06%
2001 68.773.691 20.78%
2002 92.092.381 25.32%
2003 85.387.510 -7.85%
2004 91.097.087 6.27%
2005 91.065.000 -0.04%
2006 89.068.000 -2.24%
2007 117.315.000 24.08%
2008 125.268.000 6.35%
2009 89.478.000 -40%
2010 95.363.000 6.17%
2011 97.239.000 1.93%
2012 141.893.000 31.47%
2013 6.541.000 -2069.29%
2014 7.753.000 15.63%
2015 4.019.000 -92.91%
2016 2.301.000 -74.66%
2017 7.232.000 68.18%
2018 68.895.000 89.5%
2019 52.816.000 -30.44%
2020 1.946.000 -2614.08%
2021 1.020.000 -90.78%
2022 393.842.000 99.74%
2023 388.560.000 -1.36%
2023 270.806.000 -43.48%
2024 232.996.000 -16.23%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Alkermes plc General and Administrative Expenses
Year General and Administrative Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 120.458.000 100%
2014 191.305.000 37.03%
2015 300.958.000 36.43%
2016 350.130.000 14.04%
2017 387.178.000 9.57%
2018 471.708.000 17.92%
2019 568.349.000 17%
2020 513.327.000 -10.72%
2021 522.077.000 1.68%
2022 198.551.000 -162.94%
2023 218.584.000 9.16%
2023 202.251.000 -8.08%
2024 193.652.000 -4.44%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Alkermes plc EBITDA
Year EBITDA Growth
1992 -7.400.000
1993 -43.100.000 82.83%
1994 -17.400.000 -147.7%
1995 -10.100.000 -72.28%
1996 -12.600.000 19.84%
1997 -14.850.042 15.15%
1998 -5.495.226 -170.24%
1999 -10.690.683 48.6%
2000 -69.502.790 84.62%
2001 -22.209.785 -212.94%
2002 -51.875.990 57.19%
2003 -136.457.037 61.98%
2004 -84.006.248 -62.44%
2005 -41.047.000 -104.66%
2006 25.291.000 262.3%
2007 23.514.000 -7.56%
2008 -140.330.000 116.76%
2009 156.622.000 189.6%
2010 -38.367.000 508.22%
2011 -42.903.000 10.57%
2012 6.919.000 720.08%
2013 173.832.000 96.02%
2014 -29.239.000 694.52%
2015 -163.271.000 82.09%
2016 -146.439.000 -11.49%
2017 -90.807.000 -61.26%
2018 -26.762.000 -239.31%
2019 -106.896.000 74.96%
2020 -52.371.000 -104.11%
2021 11.488.000 555.88%
2022 -96.151.000 111.95%
2023 249.448.000 138.55%
2023 486.732.000 48.75%
2024 466.164.000 -4.41%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Alkermes plc Gross Profit
Year Gross Profit Growth
1992 -4.700.000
1993 -5.700.000 17.54%
1994 10.600.000 153.77%
1995 14.500.000 26.9%
1996 16.400.000 11.59%
1997 19.826.947 17.28%
1998 31.326.648 36.71%
1999 43.715.586 28.34%
2000 22.920.357 -90.73%
2001 56.029.865 59.09%
2002 54.101.513 -3.56%
2003 36.356.053 -48.81%
2004 20.017.574 -81.62%
2005 59.292.000 66.24%
2006 143.112.000 58.57%
2007 194.756.000 26.52%
2008 200.040.000 2.64%
2009 283.443.000 29.42%
2010 128.843.000 -119.99%
2011 134.455.000 4.17%
2012 262.399.000 48.76%
2013 265.069.000 1.01%
2014 170.914.000 -55.09%
2015 144.942.000 -17.92%
2016 226.424.000 35.99%
2017 335.737.000 32.56%
2018 492.448.000 31.82%
2019 477.729.000 -3.08%
2020 465.852.000 -2.55%
2021 569.838.000 18.25%
2022 893.687.000 36.24%
2023 1.277.716.000 30.06%
2023 1.374.679.000 7.05%
2024 1.344.980.000 -2.21%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Alkermes plc Net Profit
Year Net Profit Growth
1992 -8.100.000
1993 -40.100.000 79.8%
1994 -17.300.000 -131.79%
1995 -11.900.000 -45.38%
1996 -13.700.000 13.14%
1997 -18.797.818 27.12%
1998 -9.771.131 -92.38%
1999 -41.056.370 76.2%
2000 -68.047.338 39.66%
2001 -16.869.315 -303.38%
2002 -61.354.969 72.51%
2003 -106.897.747 42.6%
2004 -102.384.561 -4.41%
2005 -73.916.000 -38.51%
2006 3.818.000 2035.99%
2007 9.445.000 59.58%
2008 166.979.000 94.34%
2009 130.505.000 -27.95%
2010 -39.626.000 429.34%
2011 -45.540.000 12.99%
2012 -113.678.000 59.94%
2013 24.983.000 555.02%
2014 -30.061.000 183.11%
2015 -227.163.000 86.77%
2016 -208.444.000 -8.98%
2017 -157.945.000 -31.97%
2018 -139.311.000 -13.38%
2019 -196.620.000 29.15%
2020 -110.861.000 -77.36%
2021 -48.169.000 -130.15%
2022 -158.267.000 69.56%
2023 191.032.000 182.85%
2023 355.757.000 46.3%
2024 365.432.000 2.65%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Alkermes plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1992 0
1993 -2 100%
1994 -1 0%
1995 0 0%
1996 0 0%
1997 -1 0%
1998 0 0%
1999 -1 0%
2000 -1 100%
2001 0 0%
2002 -1 0%
2003 -2 100%
2004 -1 0%
2005 -1 0%
2006 0 0%
2007 0 0%
2008 2 100%
2009 1 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 0 0%
2014 0 0%
2015 -2 100%
2016 -1 0%
2017 -1 0%
2018 -1 0%
2019 -1 100%
2020 -1 0%
2021 0 0%
2022 -1 0%
2023 1 100%
2023 2 50%
2024 2 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Alkermes plc Free Cashflow
Year Free Cashflow Growth
1992 -46.000.000
1993 -8.500.000 -441.18%
1994 -14.200.000 40.14%
1995 -9.700.000 -46.39%
1996 -11.100.000 12.61%
1997 -19.418.495 42.84%
1998 -9.130.960 -112.67%
1999 -38.313.863 76.17%
2000 -38.786.946 1.22%
2001 -28.007.263 -38.49%
2002 -76.065.868 63.18%
2003 -95.019.077 19.95%
2004 -113.350.394 16.17%
2005 -92.072.000 -23.11%
2006 87.870.000 204.78%
2007 47.422.000 -85.29%
2008 20.534.000 -130.94%
2009 29.088.000 29.41%
2010 -28.034.000 203.76%
2011 -15.307.000 -83.14%
2012 -19.470.000 21.38%
2013 104.334.000 118.66%
2014 -22.512.000 563.46%
2015 -93.237.000 75.86%
2016 -107.459.000 13.23%
2017 -32.110.000 -234.66%
2018 29.850.000 207.57%
2019 -18.865.000 258.23%
2020 40.623.000 146.44%
2021 72.695.000 44.12%
2022 -17.211.000 522.38%
2023 85.255.000 120.19%
2023 353.305.000 75.87%
2024 138.919.000 -154.32%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Alkermes plc Operating Cashflow
Year Operating Cashflow Growth
1992 -45.200.000
1993 -6.000.000 -653.33%
1994 -12.300.000 51.22%
1995 -9.100.000 -35.16%
1996 -5.500.000 -65.45%
1997 -17.175.019 67.98%
1998 -1.136.687 -1410.97%
1999 -14.249.342 92.02%
2000 -33.029.959 56.86%
2001 -17.988.239 -83.62%
2002 -42.681.466 57.85%
2003 -48.747.503 12.44%
2004 -98.249.224 50.38%
2005 -74.255.000 -32.31%
2006 116.530.000 163.72%
2007 83.727.000 -39.18%
2008 42.424.000 -97.36%
2009 34.590.000 -22.65%
2010 -12.247.000 382.44%
2011 -5.906.000 -107.37%
2012 -2.482.000 -137.95%
2013 126.551.000 101.96%
2014 11.139.000 -1036.11%
2015 -40.360.000 127.6%
2016 -63.802.000 36.74%
2017 19.190.000 432.48%
2018 99.281.000 80.67%
2019 72.077.000 -37.74%
2020 82.842.000 12.99%
2021 101.715.000 18.55%
2022 21.044.000 -383.34%
2023 99.708.000 78.89%
2023 401.353.000 75.16%
2024 146.030.000 -174.84%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Alkermes plc Capital Expenditure
Year Capital Expenditure Growth
1992 800.000
1993 2.500.000 68%
1994 1.900.000 -31.58%
1995 600.000 -216.67%
1996 5.600.000 89.29%
1997 2.243.476 -149.61%
1998 7.994.273 71.94%
1999 24.064.521 66.78%
2000 5.756.987 -318.01%
2001 10.019.024 42.54%
2002 33.384.402 69.99%
2003 46.271.574 27.85%
2004 15.101.170 -206.41%
2005 17.817.000 15.24%
2006 28.660.000 37.83%
2007 36.305.000 21.06%
2008 21.890.000 -65.85%
2009 5.502.000 -297.86%
2010 15.787.000 65.15%
2011 9.401.000 -67.93%
2012 16.988.000 44.66%
2013 22.217.000 23.54%
2014 33.651.000 33.98%
2015 52.877.000 36.36%
2016 43.657.000 -21.12%
2017 51.300.000 14.9%
2018 69.431.000 26.11%
2019 90.942.000 23.65%
2020 42.219.000 -115.41%
2021 29.020.000 -45.48%
2022 38.255.000 24.14%
2023 14.453.000 -164.69%
2023 48.048.000 69.92%
2024 7.111.000 -575.69%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Alkermes plc Equity
Year Equity Growth
1992 54.200.000
1993 47.700.000 -13.63%
1994 31.900.000 -49.53%
1995 21.200.000 -50.47%
1996 23.500.000 9.79%
1997 79.151.436 70.31%
1998 181.687.067 56.44%
1999 156.228.891 -16.3%
2000 167.966.995 6.99%
2001 148.409.849 -13.18%
2002 99.663.865 -48.91%
2003 -5.045.706 2075.22%
2004 75.929.949 106.65%
2005 4.112.000 -1746.55%
2006 33.216.000 87.62%
2007 203.461.000 83.67%
2008 305.314.000 33.36%
2009 434.888.000 29.79%
2010 412.616.000 -5.4%
2011 392.018.000 -5.25%
2012 853.852.000 54.09%
2013 952.374.000 10.34%
2014 1.396.837.000 31.82%
2015 1.314.275.000 -6.28%
2016 1.209.481.000 -8.66%
2017 1.202.808.000 -0.55%
2018 1.171.285.000 -2.69%
2019 1.085.442.000 -7.91%
2020 1.066.982.000 -1.73%
2021 1.112.584.000 4.1%
2022 1.043.753.000 -6.59%
2023 1.355.583.000 23%
2023 1.202.686.000 -12.71%
2024 1.284.005.000 6.33%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Alkermes plc Assets
Year Assets Growth
1992 55.700.000
1993 54.000.000 -3.15%
1994 46.300.000 -16.63%
1995 36.700.000 -26.16%
1996 45.800.000 19.87%
1997 104.697.018 56.25%
1998 220.258.097 52.47%
1999 213.452.269 -3.19%
2000 413.961.105 48.44%
2001 391.297.215 -5.79%
2002 350.350.277 -11.69%
2003 255.699.170 -37.02%
2004 270.029.504 5.31%
2005 338.874.000 20.32%
2006 477.163.000 28.98%
2007 568.621.000 16.08%
2008 656.311.000 13.36%
2009 566.486.000 -15.86%
2010 515.600.000 -9.87%
2011 452.448.000 -13.96%
2012 1.435.217.000 68.48%
2013 1.470.291.000 2.39%
2014 1.921.272.000 23.47%
2015 1.855.744.000 -3.53%
2016 1.726.423.000 -7.49%
2017 1.797.227.000 3.94%
2018 1.825.007.000 1.52%
2019 1.805.403.000 -1.09%
2020 1.949.730.000 7.4%
2021 2.024.484.000 3.69%
2022 1.963.978.000 -3.08%
2023 2.279.231.000 13.83%
2023 2.136.223.000 -6.69%
2024 2.206.842.000 3.2%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Alkermes plc Liabilities
Year Liabilities Growth
1992 1.500.000
1993 6.300.000 76.19%
1994 14.400.000 56.25%
1995 15.500.000 7.1%
1996 22.300.000 30.49%
1997 25.545.582 12.71%
1998 38.571.030 33.77%
1999 57.223.378 32.6%
2000 245.994.110 76.74%
2001 242.887.366 -1.28%
2002 250.686.412 3.11%
2003 260.744.876 3.86%
2004 194.099.555 -34.34%
2005 334.762.000 42.02%
2006 443.947.000 24.59%
2007 365.160.000 -21.58%
2008 350.997.000 -4.04%
2009 131.598.000 -166.72%
2010 102.984.000 -27.78%
2011 60.430.000 -70.42%
2012 581.365.000 89.61%
2013 517.917.000 -12.25%
2014 524.435.000 1.24%
2015 541.469.000 3.15%
2016 516.942.000 -4.74%
2017 594.419.000 13.03%
2018 653.722.000 9.07%
2019 719.961.000 9.2%
2020 882.748.000 18.44%
2021 911.900.000 3.2%
2022 920.225.000 0.9%
2023 923.648.000 0.37%
2023 933.537.000 1.06%
2024 922.837.000 -1.16%

Alkermes plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8.96
Net Income per Share
1.72
Price to Earning Ratio
15.8x
Price To Sales Ratio
2.96x
POCF Ratio
12.2
PFCF Ratio
13.65
Price to Book Ratio
3.55
EV to Sales
2.85
EV Over EBITDA
14.18
EV to Operating CashFlow
11.49
EV to FreeCashFlow
13.13
Earnings Yield
0.06
FreeCashFlow Yield
0.07
Market Cap
4,46 Bil.
Enterprise Value
4,30 Bil.
Graham Number
17.16
Graham NetNet
1.95

Income Statement Metrics

Net Income per Share
1.72
Income Quality
1.09
ROE
0.23
Return On Assets
0.15
Return On Capital Employed
0.18
Net Income per EBT
1
EBT Per Ebit
1.06
Ebit per Revenue
0.21
Effective Tax Rate
-0.16

Margins

Sales, General, & Administrative to Revenue
0.12
Research & Developement to Revenue
0.2
Stock Based Compensation to Revenue
0.07
Gross Profit Margin
0.82
Operating Profit Margin
0.21
Pretax Profit Margin
0.22
Net Profit Margin
0.22

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.11
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
2.22
Free CashFlow per Share
1.94
Capex to Operating CashFlow
0.13
Capex to Revenue
0.03
Capex to Depreciation
0.91
Return on Invested Capital
0.2
Return on Tangible Assets
0.14
Days Sales Outstanding
89.54
Days Payables Outstanding
144.48
Days of Inventory on Hand
268.6
Receivables Turnover
4.08
Payables Turnover
2.53
Inventory Turnover
1.36
Capex per Share
0.28

Balance Sheet

Cash per Share
5,21
Book Value per Share
7,63
Tangible Book Value per Share
7.13
Shareholders Equity per Share
7.63
Interest Debt per Share
1.9
Debt to Equity
0.23
Debt to Assets
0.13
Net Debt to EBITDA
-0.55
Current Ratio
2.99
Tangible Asset Value
1,20 Bil.
Net Current Asset Value
0,62 Bil.
Invested Capital
1421213000
Working Capital
1,03 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,34 Bil.
Average Payables
0,09 Bil.
Average Inventory
196550000
Debt to Market Cap
0.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Alkermes plc Dividends
Year Dividends Growth

Alkermes plc Profile

About Alkermes plc

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CEO
Mr. Richard F. Pops
Employee
2.100
Address
Connaught House
Dublin, 4

Alkermes plc Executives & BODs

Alkermes plc Executives & BODs
# Name Age
1 Mr. Blair C. Jackson
Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer
70
2 Ms. Sandra Coombs
Senior Vice President of Corporate Affairs & Investor Relations
70
3 Mr. Stephen Schiavo
Senior Vice President & Chief Human Resources Officer
70
4 Mr. Richard F. Pops
Chairman & Chief Executive Officer
70
5 Dr. Craig C. Hopkinson M.D.
Executive Vice President of Research & Development and Chief Medical Officer
70
6 Mr. David Joseph Gaffin J.D.
Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary
70
7 Mr. Iain Michael Brown
Senior Vice President & Chief Financial Officer
70
8 Mr. Samuel J. Parisi
Interim Principal Accounting Officer & Vice President of Finance
70
9 Dr. Floyd E. Bloom M.D.
Founder
70
10 Mr. Thomas Harvey
Chief Information Officer & Senior Vice President of IT
70

Alkermes plc Competitors